Search | Clinical Trials Finder

Conditions: Pre-Hypertension
Interventions: Lifestyle modification; Behavioral
Lead sponsor: Florida Heart Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Head and Neck Cancer, Carotid Artery Stenosis, Cardiovascular Complication
Interventions: Carotid ultrasound, Blood draw, Survey; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cardiovascular Disease
Interventions: Vascular surgery with best medical treatment, Coronary artery bypass grafting (CABG), Percutaneous transluminal coronary angioplasty (PTCA); Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 18
States / cities: Tucson, Arizona • No. Little Rock, Arkansas • San Francisco, California + 15 more

Conditions: Cardio-Renal Syndrome, Heart Failure, Chronic Kidney Diseases
Interventions: Fibroblast Growth Factor 23; Diagnostic Test
Lead sponsor: Coney Island Hospital, Brooklyn, NY; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Leukemia, Multiple Myeloma
Interventions: CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan; Drug
Lead sponsor: Sally Arai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more

Conditions: Coronary Atherosclerosis
Interventions: Rimonabant (SR141716), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Abdominal Aortic Aneurysm, Iliac Aneurysm, Internal Iliac Aneurysm
Interventions: Endovascular Aneurysm Repair; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Up to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Descartes 11; Biological
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Bethesda, Maryland • Hackensack, New Jersey • Oklahoma City, Oklahoma + 1 more

Conditions: Low Risk Acute Coronary Syndrome
Interventions: Stress Test, No Stress Test; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 30 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Coronary Disease, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 65 Years to 84 Years
Enrollment: 1,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
Interventions: Dynamic contrast-enhanced computed tomography, Ioversol; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes, Cardiovascular Risk
Interventions: Zenagamtide, Insulin glargine U-100; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 109
States / cities: Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more

Conditions: Atherosclerosis
Interventions: Selnoflast, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more

Conditions: Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions: Plerixafor, Gcsf; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Foot Ulcer, Diabetic
Interventions: Not listed
Lead sponsor: Temple University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder, Obesity, Hypertension, Smoking
Interventions: Rimonabant, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • Catonsville, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions: Eicosapentaenoic acid (omega-3 fatty acid), Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension, Cardiovascular Risk Factor, Physical Activity, Chronic Kidney Diseases
Interventions: FitBit; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Peripheral Arterial Disease
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Health Diagnostic Laboratory, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Camp Hill, Pennsylvania • Ephrata, Pennsylvania • Lancaster, Pennsylvania

Conditions: Acquired Immunodeficiency Syndrome, Kaposi's Sarcoma, Leukemia, Lymphoma, Tumor Virus Infection, HIV Infections
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Pravastatin, Gemfibrozil, Rosiglitazone; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study of Hispanics to Assess Risk Prevention in Prehypertension

Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy

Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality

Cardiorenal Risk Stratification Pilot Study

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Anti-VEGF Treatment for Prevention of PDR/DME

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Low Risk Acute Coronary Syndrome

Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

Activity Trackers for Improving BP

BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients

Cardiometabolic Risk in Cardiac Rehab

Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers

Endothelial Dysfunction as a Risk Factor in HIV Study